Literature DB >> 28653666

Endocannabinoid Regulation of Reward and Reinforcement through Interaction with Dopamine and Endogenous Opioid Signaling.

J M Wenzel1, J F Cheer1,2,3.   

Abstract

The endocannabinoid system (eCB) is implicated in the mediation of both reward and reinforcement. This is evidenced by the ability of exogenous cannabinoid drugs to produce hedonia and maintain self-administration in both human and animal subjects. eCBs similarly facilitate behaviors motivated by reward through interaction with the mesolimbic dopamine (DA) and endogenous opioid systems. Indeed, eCB signaling in the ventral tegmental area stimulates activation of midbrain DA cells and promotes DA release in terminal regions such as the nucleus accumbens (NAc). DA transmission mediates several aspects of reinforced behavior, such as motivation, incentive salience, and cost-benefit calculations. However, much research suggests that endogenous opioid signaling underlies the hedonic aspects of reward. eCBs and their receptors functionally interact with opioid systems within the NAc to support reward, most likely through augmenting DA release. This review explores the interaction of these systems as it relates to reward and reinforcement and examines current literature regarding their role in food reward.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28653666      PMCID: PMC5719091          DOI: 10.1038/npp.2017.126

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  181 in total

Review 1.  Neuroanatomy of dopamine: reward and addiction.

Authors:  Katherine H Taber; Deborah N Black; Linda J Porrino; Robin A Hurley
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2012       Impact factor: 2.198

Review 2.  A neural substrate of prediction and reward.

Authors:  W Schultz; P Dayan; P R Montague
Journal:  Science       Date:  1997-03-14       Impact factor: 47.728

3.  Opioid hedonic hotspot in nucleus accumbens shell: mu, delta, and kappa maps for enhancement of sweetness "liking" and "wanting".

Authors:  Daniel C Castro; Kent C Berridge
Journal:  J Neurosci       Date:  2014-03-19       Impact factor: 6.167

4.  A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice.

Authors:  E Valjent; R Maldonado
Journal:  Psychopharmacology (Berl)       Date:  2000-01       Impact factor: 4.530

5.  Glutamatergic and nonglutamatergic neurons of the ventral tegmental area establish local synaptic contacts with dopaminergic and nondopaminergic neurons.

Authors:  Alice Dobi; Elyssa B Margolis; Hui-Ling Wang; Brandon K Harvey; Marisela Morales
Journal:  J Neurosci       Date:  2010-01-06       Impact factor: 6.167

6.  The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Authors:  Zuzana Justinova; Gianluigi Tanda; Patrik Munzar; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

7.  Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol.

Authors:  Tim C Kirkham; Claire M Williams; Filomena Fezza; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

8.  Burst firing of mesencephalic dopamine neurons is inhibited by somatodendritic application of kynurenate.

Authors:  P J Charlety; J Grenhoff; K Chergui; B De la Chapelle; M Buda; T H Svensson; G Chouvet
Journal:  Acta Physiol Scand       Date:  1991-05

9.  Involvement of dopamine and opioids in the motivation to eat: influence of palatability, homeostatic state, and behavioral paradigms.

Authors:  M Flavia Barbano; Maryvonne Le Saux; Martine Cador
Journal:  Psychopharmacology (Berl)       Date:  2008-11-18       Impact factor: 4.530

10.  Morphine disinhibits glutamatergic input to VTA dopamine neurons and promotes dopamine neuron excitation.

Authors:  Ming Chen; Yanfang Zhao; Hualan Yang; Wenjie Luan; Jiaojiao Song; Dongyang Cui; Yi Dong; Bin Lai; Lan Ma; Ping Zheng
Journal:  Elife       Date:  2015-07-24       Impact factor: 8.140

View more
  35 in total

1.  Selective breeding for high alcohol preference is associated with increased sensitivity to cannabinoid reward within the nucleus accumbens shell.

Authors:  Sheketha R Hauser; Simon N Katner; Robert A Waeiss; William A Truitt; Richard L Bell; William J McBride; Zachary A Rodd
Journal:  Pharmacol Biochem Behav       Date:  2020-07-23       Impact factor: 3.533

2.  Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide).

Authors:  Erin C Hanlon
Journal:  Psychoneuroendocrinology       Date:  2019-10-04       Impact factor: 4.905

Review 3.  The dopamine motive system: implications for drug and food addiction.

Authors:  Nora D Volkow; Roy A Wise; Ruben Baler
Journal:  Nat Rev Neurosci       Date:  2017-11-16       Impact factor: 34.870

4.  Cannabis and Cannabinoids: From Synapse to Society.

Authors:  Margaret Haney; Matthew N Hill
Journal:  Neuropsychopharmacology       Date:  2018-01       Impact factor: 7.853

5.  Chemogenetic Manipulations of Ventral Tegmental Area Dopamine Neurons Reveal Multifaceted Roles in Cocaine Abuse.

Authors:  Stephen V Mahler; Zachary D Brodnik; Brittney M Cox; William C Buchta; Brandon S Bentzley; Julian Quintanilla; Zackary A Cope; Edwin C Lin; Matthew D Riedy; Michael D Scofield; Justin Messinger; Christina M Ruiz; Arthur C Riegel; Rodrigo A España; Gary Aston-Jones
Journal:  J Neurosci       Date:  2018-11-16       Impact factor: 6.167

6.  Δ9-tetrahydrocannabinol attenuates oxycodone self-administration under extended access conditions.

Authors:  Jacques D Nguyen; Yanabel Grant; Kevin M Creehan; Candy S Hwang; Sophia A Vandewater; Kim D Janda; Maury Cole; Michael A Taffe
Journal:  Neuropharmacology       Date:  2019-04-11       Impact factor: 5.250

7.  Detection of Cyclooxygenase-2-Derived Oxygenation Products of the Endogenous Cannabinoid 2-Arachidonoylglycerol in Mouse Brain.

Authors:  Amanda J Morgan; Philip J Kingsley; Michelle M Mitchener; Megan Altemus; Toni A Patrick; Andrew D Gaulden; Lawrence J Marnett; Sachin Patel
Journal:  ACS Chem Neurosci       Date:  2018-05-09       Impact factor: 4.418

Review 8.  Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.

Authors:  Reda M Chalhoub; Peter W Kalivas
Journal:  Drugs       Date:  2020-10       Impact factor: 9.546

9.  Cannabidiol Prevents the Expression of the Locomotor Sensitization and the Metabolic Changes in the Nucleus Accumbens and Prefrontal Cortex Elicited by the Combined Administration of Cocaine and Caffeine in Rats.

Authors:  José Pedro Prieto; Ximena López Hill; Jessika Urbanavicius; Verónica Sanchez; Xavier Nadal; Cecilia Scorza
Journal:  Neurotox Res       Date:  2020-05-15       Impact factor: 3.911

10.  Local μ-Opioid Receptor Antagonism Blunts Evoked Phasic Dopamine Release in the Nucleus Accumbens of Rats.

Authors:  Alexander Gómez-A; Tatiana A Shnitko; Haley M Barefoot; Eleanor L Brightbill; Leslie A Sombers; Saleem M Nicola; Donita L Robinson
Journal:  ACS Chem Neurosci       Date:  2018-11-06       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.